EUGLYCEMIC DIABETIC KETOACIDOSIS SECONDARY TO EMPAGLIFLOZIN USE

被引：0

作者：

Abbasi, Anna ^{[1
]}

Nguyen, Tina ^{[1
]}

Gupta, Sushilkumar ^{[1
]}

Yoon, Taek Sang ^{[1
]}

机构：

[1] Maimonides Hosp, Brooklyn, NY USA

来源：

CHEST | 2019年 / 156卷 / 04期

关键词：

D O I：

10.1016/j.chest.2019.08.2047

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

收藏

页码：2101A / 2102A

页数：2

相关论文

共 3 条

[1] Euglycemic Diabetic Ketoacidosis in a 27 year-old female patient with type-1-Diabetes treated with sodium-glucose cotransporter-2 (SGLT2) inhibitor Canagliflozin
Bader, Nimrah
Mirza, Lubna
[J]. PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2016, 32 (03) : 786 - 788
[2] Rawla P, 2017, ENDOCRINOL DIAB META, DOI 10.1530/EDM-17-0081
[3] Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors
Rosenstock, Julio
Ferrannini, Ele
[J]. DIABETES CARE, 2015, 38 (09) : 1638 - 1642